Biphasic MLL takes helm at cell cycle control: Implications in human mixed lineage leukemia by Liu, Han et al.




Biphasic MLL takes helm at cell cycle control:
Implications in human mixed lineage leukemia
Han Liu
Washington University School of Medicine in St. Louis
Shugaku Takeda
Washington University School of Medicine in St. Louis
Emily H.Y. Cheng
Washington University School of Medicine in St. Louis
James J.D. Hsieh
Washington University School of Medicine in St. Louis
Follow this and additional works at: http://digitalcommons.wustl.edu/open_access_pubs
This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been accepted for inclusion in Open
Access Publications by an authorized administrator of Digital Commons@Becker. For more information, please contact engeszer@wustl.edu.
Recommended Citation
Liu, Han; Takeda, Shugaku; Cheng, Emily H.Y.; and Hsieh, James J.D., ,"Biphasic MLL takes helm at cell cycle control: Implications in
human mixed lineage leukemia." Cell Cycle.7,4. 428-435. (2008).
http://digitalcommons.wustl.edu/open_access_pubs/3018
[Cell Cycle 7:4, 428-435; 15 February 2008]; ©2008 Landes Bioscience
428 Cell Cycle 2008; Vol. 7 Issue 4
Discovered in 1992 from cloning the gene involved in human 
leukemias carrying chromosome band 11q23 translocations, the 
MLL/HRX/ALL-1 gene has since attracted scientists from various 
disciplines by its diverse functions in normal physiological and 
pathological processes. MLL is the human orthologue of Drosophila 
trithorax (trx)—the founding member of trithorax group proteins, 
Trx-G. Leukemogenic11q23 translocations fuse the common MLL 
N-terminal 1400aa in-frame with a wide variety of fusion partners 
that share no structural or functional homology. The 500 kD 
precursor MLL undergoes evolutionarily conserved site-specific 
cleavage mediated by Taspase1, generating the mature MLLN320/
C180 heterodimer which methylates histone H3 at lysine 4 with its 
carboxy-terminal SET domain. Extensive biochemical and genetic 
studies on MLL/trx have established its critical role in maintaining 
the expression of Hox/homeotic genes. By contrast, the involvement 
of MLL in many other essential cellular processes remains unclear. 
Recent reports including ours began to elucidate the intricate 
interplay between MLL and the cell cycle machinery, which ensures 
proper cell cycle phase transitions. Thus, this review will focus 
on this novel activity of MLL and discuss the implications of its 
deregulation in MLL leukemias.
The MLL Leukemia
Although modern therapy for acute leukemia has improved 
greatly, there are genetic subsets of patients who respond very poorly 
to chemotherapy or relapse shortly post induction chemotherapy. 
Leukemias with chromosome band 11q23 translocations are associ-
ated with early relapse, which involves the human Mixed Lineage 
Leukemia (MLL/HRX/ALL-1) gene.1-12 MLL translocations are 
found in at least 10% of de novo ALL and AML in children and 
adults. Of note, 80% of acute lymphoblastic leukemia (ALL) and 
acute myeloid leukemia (AML) that arise in infants, and almost 
all cases of secondary AML that arise after treatment with topoi-
somerase II inhibitors are associated with MLL translocations. The 
leukemia blasts in infant ALL are usually CD19+, HLA-DR+, TdT+, 
CALLA- and cytoplasmic Ig-, consistent with an early precursor B-
ALL. Furthermore, they also express the myelomonocytic marker, 
CD15.13-15 The mixed phenotype of these blasts has led to a 
proposal that 11q23 abnormalities transform a multipotent stem cell 
or interrupt a differentiating cell.
Based on gene expression profiles, several groups had reported 
that ALL possessing a rearranged MLL exhibits a highly uniform 
and distinct pattern that clearly distinguishes them from conven-
tional ALL or AML.16-18 Their gene expression profiles are 
consistent with an early hematopoietic progenitor stage, expressing 
select multi-lineage markers and individual HOX genes. Studies 
using retrovirus-mediated gene transduction of MLL-Fusions in 
purified hematopoietic progenitors established that MLL leuke-
mias can arise from hematopoietic stem cells (HSC), common 
myeloid progenitors (CMP), and granulocytic/monocytic-restricted 
progenitors (GMP), but not megakaryocytic/erythroid-restricted 
progenitors (MEP).19-21
Fucntions of the MLL Gene
Located at the human chromosome band 11q23 breakpoints, 
MLL is the mammalian counterpart of Drosophila trithorax (Trx), the 
founder of trithorax group (Trx-G) genes.22-27 It is well characterized 
that trithorax group (Trx-G) proteins antagonize with polycomb 
group (Pc-G) proteins for proper Hox/homeotic gene expression 
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through chromatin modifications.28-30 As a transcription coacti-
vator, MLL/Trx is required for the maintenance of spatial patterns 
of Hox and HOM-C (homeotic complex) genes in vertebrates and 
invertebrates, respectively. Homozygous deficiency for MLL results 
in early embryonic lethality at embryonic day 10.5 (E10.5), exhib-
iting multiple patterning defects, and heterozygous deletion of MLL 
incurs homeotic transformation, indicating altered Hox gene expres-
sion.31-33 Recent studies also indicated an essential role of MLL in 
hematopoiesis.34,35
The MLL gene encodes a 3,969 amino acid, 500 kD protein 
consisting of multiple conserved domains with distinct biochemical 
properties (Fig. 1). (1) Three AT hooks, found near the N-terminus 
of MLL, mediate its binding to the minor groove of AT-rich DNA 
region.36 (2) A transcription repression domain consists of a cysteine-
rich CXXC DNMT (DNA methyltransferase1) homology region.37 
(3) Four PHD fingers mediate protein-protein interactions.38 (4) 
A transactivation (TA) domain interacts with p300/CBP.39 (5) A 
C-terminal SET domain functions as a histone methyl transferase 
(HMT) that methylates Histone H3 at K4, marking transcription-
ally active genes.40,41 Over the years, a plethora of MLL interaction 
partners have been identified, providing additional mechanistic 
insights regarding how MLL regulates complex gene expression. MLL 
complexes with Menin (a tumor suppressor),42,43 cell cycle regula-
tors (E2Fs and HCF),43-45 Pc-G proteins (Bmi-1 and HPC2),37 
HDACs (Histone Deacetylases),41 Cyp33 (a nuclear cyclophilin),37 
CBP/P300 (Histone acetylase),39 INI1/SNF5 (chromatin remodeling 
factors)46 and core components of the H3K4 histone methyl trans-
ferase (WDR5 and Rbbp5).47,48
In addition to the aforementioned complexity of MLL gene 
regulation, we and others showed that the 500 kD full length 
MLL precursor (MLLFL) undergoes evolutionarily conserved site-
specific proteolysis to generate a mature MLLN320/C180 heterodimer, 
consisting of the processed N-terminal 320 kD and C-terminal 180 
kD fragments.41,49-51
Taspase1 Cleaves MLL: An Essential Step in MLL Activation
Proteolysis of MLL is an evolutionarily conserved process in 
that canonical cleavage sites (QV(L)D/GXXD) exist among all 
MLL orthologues from insects to vertebrates.50 To understand the 
biological significance of MLL cleavage, we purified the respon-
sible protease.51 Biochemical purification of the MLL processing 
enzyme identified a previously uncharacterized orf13 (open reading 
frame) on human chromosome 20 (c20orf13). Detailed studies of 
c20orf13 confirmed that it encodes the bona fide protease mediating 
MLL proteolysis both in vitro and in vivo.51 We named it Taspase1 
(threonine aspartase 1) and the discovery of Taspase1 founded a new 
class of endopeptidases that utilize the N-terminal threonine of its 
mature β subunit as the active site nucleophile to cleave polypeptide 
substrates after an aspartate.51 Taspase1 encodes a highly conserved 
420 aa proenzyme which undergoes intramolecular proteolysis to 
produce an active α28/β22 heterodimer.51 The Taspase1 heterodimer 
displays an overall α/β/β/α structure which further assembles into an 
Figure 1. A diagram depicts the regulatory cascades initiated by the Taspase1-mediated cleavage of MLL. Taspase1 proenzyme undergoes autoproteolysis 
to form the mature α28/β22 protease which cleaves precursor MLL at conserved cleavage site (CS) to generate N-terminal 320 kD and C-terminal 180 kD 
fragments which heterodimerize as a fully functional histone H3 K4 methyl transferase. MLL actively participates in cell cycle progression (Left) and embryonic 
development (Right) through directly controlling cell cycle genes and HOX clusters, respectively. The four human HOX clusters are outlined. The activity of 
MLL is kept in check by the cell cycle UPS, thus facilitating the accurate execution of the cell progression cycle. T denotes threonine.
Mll in the cell cycle driver’s seat
430 Cell Cycle 2008; Vol. 7 Issue 4
 asymmetric α2/β2 heterotetramer.52 In addition to MLL family 
proteins, we also identified TFIIA family proteins, TFIIAα-β and 
ALF, and Drosophila HCF as novel Taspase1 substrates.53,54
We created Taspase1 deficient mice to investigate its participation 
in diverse signaling pathways. In the absence of Taspase1, MLL and 
its close homologue, MLL2, exist as uncleaved full length precur-
sors.44 Importantly, precursor MLL (MLLFL) exhibits impaired 
HMT activity.44 Consequently, Taspase1-/- mice manifest with clas-
sical homeotic transformation resulted from deregulated Hox gene 
expression, in consistence with our proposed model51 (Fig. 1). Our 
biochemical and genetic studies demonstrate that uncleaved MLLFL 
functions as a hypomorphic mutant. In other words, Taspase1-medi-
ated proteolysis constitutes a post-translational program in activating 
precursor MLL. These observations provide the mechanistic basis 
explaining deficits associated with a hypomorphic Drosophila Trx 
allele (TrxE3),55 which contains an in-frame deletion of the predicted 
Taspase1 cleavage site, thus generating a noncleavable Trx. Taken 
together, Taspase1-mediated cleavage of MLL/Trx is an evolution-
arily conserved regulatory event that ensures a correct spatial and 
temporal activation of MLL/Trx downstream targets.
Homozygous disruption of MLL in mice results in early embry-
onic lethality and heterozygous deficiency results in homeotic 
transformation due to impaired maintenance of Hox genes.31 The 
early lethality of MLL-/- mouse embryos precludes detailed inves-
tigation of its involvement in other signalling pathways. Although 
the underlying mechanisms were not further investigated, initial 
characterizations on MLL-/- mice suggest a role of MLL in prolifera-
tion in addition to differentiation. For example, MLL-/- fetal liver or 
yolk sac hematopoietic cells grow slower and form smaller colonies 
in methyl cellulose assays.32,56 Our demonstration that MLL is regu-
lated by Taspase1-mediated proteolytic cleavage broadens the avenue 
in studying MLL in that non-cleaved precursor MLL functions as a 
hypomorphic mutant.44
In addition to the predicted homeotic transformation resulted 
from altered Hox gene expression, our studies on Taspase1-/- animals 
uncovered an essential role of Taspase1 in orchestrating cell cycle 
progression—Taspase1 deficiency causes defects in cell cycle regu-
lation.44 Mechanistic studies revealed deregulated expression of 
key cell cycle regulators, including downregulation of Cyclin E, A, 
B and upregulations of p16Ink4a and ARF. MLL and MLL2 are 
critical substrates in Taspase1-mediated cell cycle control, which was 
confirmed by the proliferation defects in MLLnc/nc;2nc/nc MEFs (cells 
carry double homozygous noncleavable (nc) knockin alleles of MLL 
and MLL2). MLLs interact with E2Fs, core transcription factors of 
the cell cycle, to modulate expression of Cyclins. MLL proteolysis by 
Taspase1 is required to generate a fully functional mature MLLN320/
C180 heterodimer. The uncleaved full length precursor MLLFL is 
inefficient in histone H3 methylation both in vivo and in vitro.44 
Taken together, full length precursor MLLFLs, following cleavage 
by Taspase1, target to Cyclins through their interactions with E2Fs 
to methylate histone H3 at K4, thus activating cell cycle regulatory 
genes.44
The Intricate Interplay Between MLL and Cell Cycle Machinery
Eukaryotic cell cycle consists of a tightly orchestrated circular 
progression of a sequence of distinct phases—namely G1, S, G2 and 
M—designated for the execution of inherent genetic programs.57 
Key regulatory components of the mammalian cell cycle machinery 
include E2Fs, Rbs, Cyclins, Cyclin dependent kinases (CDKs), and 
CDK inhibitors (CDKIs), which form complex positive and nega-
tive epistatic circuits to ensure accurate cell cycle progression.58 The 
molecular blueprint of a normal cell cycle details the central controls 
held by a series of CDKs which positively influence proliferation 
through phosphorylatioin of target proteins such as Rbs.59 This 
releases the repressive activities of Rbs on E2Fs—executors of the 
cell cycle genetic program.60-64 Individual CDKs need to complex 
with specialized Cyclins to form catalytically active CDK/Cyclins. 
Therefore, their activities depend on the availability of involved 
Cyclins. Additional regulation of CDK/Cyclins comes from negative 
factors, the CDKIs.65 Levels of Cyclins and CDKIs undulate during 
the cell division cycle, which in part is due to defined windows of 
degradation by the ubiquitin-proteasome system (UPS).66 UPS 
commences at substrate recognition and the subsequent covalent 
conjugation of ubiquitin by responsible E3 ligases, followed by 
degradation executed by the 26S proteasome.67 The two major 
E3 complexes involved in proteolyzing core components of the 
cell cycle machinery are SCF (Skp1-Cul1-F-box protein) and APC 
(anaphase-promoting complex/cyclosome) complexes, of which the 
substrate recognition is conducted by the variable components—F 
box proteins for SCF, and Cdc20 or Cdh1 for APC.68-70 Thus, two 
types of post-translational modifications—phosphorylation and 
ubiquitination—constitute the two main controls of cell cycle.
Our studies on cells deficient for Taspase1 or bearing non-cleav-
able alleles of MLL, MLLnc/nc, recognize the participation of MLL 
through E2Fs in regulating cell proliferation, linking MLL prote-
olysis to the heart of cell cycle gene programming.44 The essential 
role of MLL in cell cycle progression through the MLL-E2F axis is 
further supported by a recent report indicating that HCF-1, MLL 
and E2F form tertiary complex on E2F-responsive promoters during 
the G1/S phase transition, thereby inducing histone methylation and 
transcriptional activation.45 The active involvement of MLL/Trx in 
the cell cycle is conserved through evolution in that genetic studies in 
Drosophila also highlight a critical role of Trx in cell proliferation.71 
Additionally, several recent reports also identified MLL as a direct 
activator of Cyclins and CDKIs.44,45,72,73
To further investigate how MLL regulates the cell cycle, we 
examined protein level of MLL through the cell cycle and observed a 
tightly controlled biphasic expression of MLL in all cell types.74 This 
unique expression is conferred by defined windows of degradation 
mediated by specialized cell cycle E3 ligases, SCFSkp2 and APCCdc20 
(Fig. 1).74 Importantly, two peak expressions of MLL ensure corre-
sponding G1/S transition and M phase progression. Disruption of 
this unique expression pattern by shRNA-mediated knockdown 
of MLL causes defects in G1/S entry and M phase progression.
74 
Furthermore, overexpression of MLL incurs specific S phase defects, 
indicating the importance of downregulating its activity in the S 
phase. However, whether this is resulted from sustained expression 
of downstream key cell cycle regulators, and/or overexpressed MLL 
invoked yet identified insults remains to be determined.
These data not only highlight the significance of biphasic MLL 
expression in orchestrating cell division cycle but also uncover a novel 
mechanism by which the cell cycle machinery regulates MLL.74 This 
establishes another irreversible post-translational regulation of MLL 
through degradation in addition to Taspase1-mediated site-specific 
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proteolysis. As MLL directly activates tran-
scription of Cyclins that exhibit periodic 
expression during cell proliferation, it is 
imperative for a cell to incorporate MLL 
expression into the intricately assembled 
cell cycle circuitry, ensuring a correct tran-
sition of progressive phases.
It seems counterintuitive at the first 
glance that MLL/Trx activates both 
Cyclins44,45 and CDKIs,72,73 positive 
and negative regulators of the cell cycle, 
respectively. It is plausible that MLL/Trx 
targets downstream genes in a cell cycle 
phase-dependent manner. Indeed, a cell 
cycle specific recruitment of MLL/Trx to 
its target genes such as CyclinA has been 
reported.45 Biphasic expression of MLL 
assures target genes to be activated and 
inactivated following a tightly choreo-
graphed temporal sequence. Based on 
available reports, we propose the following 
model detailing how MLL coordinates 
the G1/S transition (Fig. 2).
44,45,73-76 In 
the mid-G1 phase, the rising MLL level 
activates both p27 and CyclinE that assemble into an inactive 
CDK2/CyclinE/p27 complex which prepares the cell for G1/S entry. 
In the late G1 phase, MLL further activates CyclinE leading to an 
excess of active CDK2/CyclinE complex that marks p27 for degra-
dation through phosphorylation. Downregulated p27 along with the 
concurrent increase of CyclinE eventually marshals cells through the 
G1/S transition. Once entering the G1/S transition, MLL is recruited 
to the promoter of CyclinA.45 Increased CyclinA replaces CyclinE, 
thereby facilitating the assembly of CDK2/CyclinA complex for S 
phase progression. Upon a successful entry into the S phase, MLL is 
no longer needed and thus degraded by the SCFSkp2 E3 ligase (Fig. 
2).
Models of the MLL Leukemia
Human chromosome 11q23 aberrations disrupting MLL lead to 
infant and therapy-related leukemias. These balanced translocations 
fuse the N-terminal ~1400 aa of MLL in-frame with a wide spec-
trum of fusion partners, generating pathognomonic leukemogenic 
MLL-Fusions. Mysteriously, among these (>50) fusion partners, 
no shared characteristics were recognized based on sequence or 
structure homology.1-11 Genetic studies on mice carrying individual 
MLL-Fusions reveal several fundamental aspects concerning the 
MLL leukemia. First, MLL-Fusions from 11q23 translocations are 
responsible for the leukemogenesis.77-81 Second, fusion partners are 
indispensable.82 Third, partners can be as non-specific as bacterial 
galactosidase (LacZ) in that mice bearing MLL-LacZ developed 
myeloid leukemias after a prolonged latency.82 Fourth, individual 
partners determine the phenotypes of resulting leukemias. For 
example, mice carrying MLL-AF4 or MLL-AF9 develop lymphoid 
versus myeloid malignancies, mimicking their respective human 
counterparts.78,80,83 Detailed analyses of individual MLL-Fusions 
using retrovirus-mediated gene transduction of hematopoietic stem/
progenitor cells provide insightful mechanistic explanations regarding 
the MLL leukemia.84-89 These studies established important models 
such as transactivation and dimerization—emphasizing the gain of 
Hox gene expression, thus interfering blood lineage commitment 
(Fig. 3).85,90-92 However, these two models are only suitable for 
subsets of MLL leukemias since not all fusion partners contain trans-
activation or dimerization domains.
As mice bearing MLL-LacZ developed leukemias, it has been 
postulated that LacZ induces leukemias through either oligo-
merizing or stabilizing the MLL N-terminus—two non-mutually 
exclusive mechanisms.82 Although stabilization may contribute 
to MLL leukemogenesis, it has not been further examined. Our 
initial studies on the site-specific proteolysis of MLL indicated that 
proteolytic cleavages of MLL not only regulates its activation but 
also stability.50 Based on our prior studies on the unstable nature 
of MLL N-terminus, we had proposed a model in which fusion 
partners stabilize the common MLL N-terminus for downstream 
gene regulation—a mechanism compatible with the prevailing 
activation and dimerization models.50 In a recent report, we further 
investigated this mechanism and discovered that degradation of MLL 
initiates at its N-terminal ~1400 aa that is universally retained in all 
documented MLL leukemia fusions.74 Importantly, the prevalent 
MLL-Fusions, including MLL-AF4, MLL-AF9, MLL-ENL and 
MLL-ELL, and leukemogenic MLL-LacZ all exhibit resistance to 
degradation mediated by respective cell cycle UPS. This is in part due 
to the diminished interaction between N-terminal MLL and Skp2 or 
Cdc20, which results in an uncontrolled constant presence of MLL-
Fusions through the cell cycle.74
As activation and dimerization models are only applicable to 
certain MLL-Fusions, a unifying model could exist to explain the 
wide variety of fusion partners. As MLL-LacZ is resistant to cell cycle 
phase-specific degradation, it is possible that partner proteins with 
oligomerizing capacity stabilize the respective MLL-Fusions (Fig. 3). 
Consequently, MLL target genes become constantly activated due 
Figure 2. A proposed model details the orchestration of G1/S transition by MLL.
Mll in the cell cycle driver’s seat
432 Cell Cycle 2008; Vol. 7 Issue 4
to unmonitored expression of MLL-Fusions. Our studies uncovered 
a functional commonality among structurally diversified fusion 
partners, which yields a model in which partners interfere with 
the recognition of respective MLL-Fusions by cell cycle E3 ligases, 
resulting in their non-oscillating expression (Fig. 3). Importantly, 
our stabilization model is mechanistically compatible with and 
likely constitutes the basis underlying established transactivation and 
dimerization models, explaining the myriad fusion partners with no 
structural analogy (Fig. 3).
The Contributions of Cell Cycle Deregulation to MLL 
Leukemias
HOX gene clusters encode highly conserved transcription factors 
with critical roles in embryonic development and hematopoiesis.93,94 
As HOX genes are the best characterized MLL targets, significance of 
their deregulation in MLL leukemias has been extensively studied.95-
98 Hox deregulation is required for certain but not all MLL-Fusions 
induced leukemias. For instance, HoxA7 and HoxA9 are prerequisite 
for MLL-ENL initiated leukemia95 but are dispensable for leukemias 
induced by MLL-AF9 and MLL-GAS7.96,97 Therefore, it is likely 
that deregulation of critical pathways other than Hox genes plays 
an instrumental role in MLL leukemias. A few reports including 
ours have begun to explore the roles of MLL/MLL-Fusions in cell 
cycle, genome integrity, etc.,—an uncharted area demanding further 
efforts.44,71-74,99,100 Initial emphasis on Hox gene deregulation 
provides an important yet oversimplified view concerning the MLL 
leukemia. Hence, future elucidation and validation of additional 
signaling pathways controlled by MLL and their respective deregula-
tion incurred by MLL-Fusions would likely yield novel targets for 
future treatment of the MLL leukemia.
Our observed cell cycle defects from perturbations of MLL 
expression led to hypothesize that MLL-Fusions interfere with the 
cell cycle, which is supported by prior overexpression studies using 
either MLL-AF4 or MLL-AF9.71,72 The resistance of MLL-Fusion 
to cell cycle phase-specific degradation results in its non-oscillating 
expression during the cell division cycle.74 Although the conse-
quences of such deregulated expression remain to be determined, 
the loss of temporal control of MLL targets likely contributes to the 
ultimate MLL leukemia phenotype.71,72,101 
The Trx-G and Pc-G in Oncogenesis
Genetic evidences obtained from 
studying flies and mammals establish 
the fundamental roles of Pc-G and Trx-
G proteins in maintaining Hox/homeotic 
gene expression, thus ensuring the correct 
instalment of complex segmental body 
plans in higher organisms. Recent studies 
revealed an even more perplexed relation-
ship between these two groups of proteins 
in regulating non-Hox/homeotic pathways. 
For example, they target similar cell cycle 
genes such as CyclinA and p16.44,102,103 
Furthermore, deregulation of factors 
belonging to either groups affects hemato-
poiesis and contributes to various oncogenic 
processes.34,35,104,105
Bmi-1, a Pc-G protein, is well recognized for its ability to accel-
erate Myc-induced lymphoma in mice.103 Subsequent studies on 
Bmi-1-associated oncogenesis primarily emphasize on the ability of 
Bmi-1 to suppress the expression of tumour suppressors, p16Ink4a 
and ARF, thus promoting caner cell proliferation.106 Surprisingly, 
despite its well established role in Hox gene regulation, the signifi-
cance of Bmi-1-induced Hox gene alterations in Bmi-1-mediated 
oncogenesis remains undetermined. On the contrary, studies on 
MLL, the founder of Trx-G proteins, and its associated leukemias 
clearly recognize the potential mechanistic importance of overexpres-
sion of Hox genes in leukemogenesis. Similarly, whether aberrant cell 
cycle gene expression contributes to MLL leukemogenesis remains 
undetermined. Based on our findings linking MLL/MLL Fusions to 
the cell cycle regulation, we propose that a simultaneous deregula-
tion of differentiation and proliferation through Hox and cell cycle 
genes by Bmi-1 and MLL is of paramount importance in respective 
carcinogenesis (Fig. 4).
Conclusions and Future Directions
Although our recent studies elucidated the intimate relationship 
between MLL and the cell cycle control,44,74 the in vivo conse-
quences incurred by non-oscillating expression of MLL-Fusions 
remain to be elucidated. Studies by us and others clearly indicate the 
importance to avoid expressing MLL/MLL-Fusions at a nonphysi-
ological level—expression of MLL/MLL-Fusions beyond or below 
the physiological range incurs undesirable cell cycle consequences 
that may easily lead to an erroneous conclusion. Therefore, to criti-
cally examine cell cycle defects associated with MLL-Fusions, one has 
to employ cells bearing knockin allele of MLL-Fusion of which its 
expression is directly controlled by the endogenous MLL promoter.
The most characterized biochemical property of MLL is its 
activity to methylate Histone H3 at K4 position with its C-terminal 
SET domain, thus marking the active epigenome. However, this 
highly conserved SET domain only represents less than 5% of MLL 
which is made of 3,969 amino acid residues. Furthermore, the ubiq-
uitous expression of MLL implicates its participation in essential 
cellular processes other than cell fate decisions. Recent positioning 
of MLL in the cell division cycle inaugurated the search for non-
canonical functions of MLL. Although it has been a decade since its 
Figure 3. A schematic model integrates various models of the MLL leukemia.
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debut, there are treasures ahead awaiting future discoverers. Hence, 
we anticipate to witnessing exciting discoveries of unrecognized 
critical functions of the multi-talented MLL protein by scientists 
from various disciplines.
References
 1. Downing JR, Look AT. MLL fusion genes in the 11q23 acute leukemias. Cancer Treat Res 
1996; 84:73-92.
 2. Look AT. Oncogenic transcription factors in the human acute leukemias. Science 1997; 
278:1059-64.
 3. Rowley JD. The critical role of chromosome translocations in human leukemias. Annu Rev 
Genet 1998; 32:495-519.
 4. Ayton PM, Cleary ML. Molecular mechanisms of leukemogenesis mediated by MLL fusion 
proteins. Oncogene 2001; 20:5695-707.
 5. Ernst P, Wang J, Korsmeyer SJ. The role of MLL in hematopoiesis and leukemia. Curr Opin 
Hematol 2002; 9:282-7.
 6. Canaani E, Nakamura T, Rozovskaia T, Smith ST, Mori T, Croce CM, Mazo A. ALL-
1/MLL1, a homologue of Drosophila TRITHORAX, modifies chromatin and is directly 
involved in infant acute leukaemia. Br J Cancer 2004; 90:756-60.
 7. Popovic R, Zeleznik-Le NJ. MLL: how complex does it get? J Cell Biochem 2005; 
95:234-42.
 8. Daser A, Rabbitts TH. Extending the repertoire of the mixed-lineage leukemia gene MLL 
in leukemogenesis. Genes Dev 2004; 18:965-74.
 9. Gilliland DG, Jordan CT, Felix CA. The molecular basis of leukemia. Hematology (Am Soc 
Hematol Educ Program) 2004:80-97.
 10. Hess JL. Mechanisms of transformation by MLL. Crit Rev Eukaryot Gene Expr 2004; 
14:235-54.
 11. Eguchi M, Eguchi-Ishimae M, Greaves M. Molecular pathogenesis of MLL-associated 
leukemias. Int J Hematol 2005; 82:9-20.
 12. Krivtsov AV, Armstrong SA. MLL translocations, histone modifications and leukaemia 
stem-cell development. Nat Rev Cancer 2007; 7:823-33.
 13. Parkin JL, Arthur DC, Abramson CS, McKenna RW, Kersey JH, Heideman RL, Brunning RD. 
Acute leukemia associated with the t(4;11) chromosome rearrangement: ultrastructural and 
immunologic characteristics. Blood 1982; 60:1321-31.
 14. Nagasaka M, Maeda S, Maeda H, Chen HL, Kita K, Mabuchi O, Misu H, Matsuo T, 
Sugiyama T. Four cases of t(4;11) acute leukemia and its myelomonocytic nature in infants. 
Blood 1983; 61:1174-81.
 15. Stong RC, Korsmeyer SJ, Parkin JL, Arthur DC, Kersey JH. Human acute leukemia cell 
line with the t(4;11) chromosomal rearrangement exhibits B lineage and monocytic charac-
teristics. Blood 1985; 65:21-31.
 16. Armstrong SA, Staunton JE, Silverman LB, Pieters R, den Boer ML, Minden MD, Sallan SE, 
Lander ES, Golub TR, Korsmeyer SJ. MLL translocations specify a distinct gene expression 
profile that distinguishes a unique leukemia. Nat Genet 2002; 30:41-7.
 17. Yeoh EJ, Ross ME, Shurtleff SA, Williams WK, Patel D, Mahfouz R, Behm FG, Raimondi SC, 
Relling MV, Patel A, Cheng C, Campana D, Wilkins D, Zhou X, Li J, Liu H, Pui CH, 
Evans WE, Naeve C, Wong L, Downing JR. Classification, subtype discovery, and predic-
tion of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. 
Cancer Cell 2002; 1:133-43.
 18. Ferrando AA, Armstrong SA, Neuberg DS, Sallan SE, Silverman LB, Korsmeyer SJ, Look AT. 
Gene expression signatures in MLL-rearranged T-lineage and B-precursor acute leukemias: 
dominance of HOX dysregulation. Blood 2003; 102:262-8.
 19. Somervaille TC, Cleary ML. Identification and characterization of leukemia stem cells in 
murine MLL-AF9 acute myeloid leukemia. Cancer Cell 2006; 10:257-68.
 20. Cozzio A, Passegue E, Ayton PM, Karsunky H, Cleary ML, Weissman IL. Similar MLL-
associated leukemias arising from self-renewing stem cells and short-lived myeloid progeni-
tors. Genes Dev 2003; 17:3029-35.
 21. Krivtsov AV, Twomey D, Feng Z, Stubbs MC, Wang Y, Faber J, Levine JE, Wang J, Hahn WC, 
Gilliland DG, Golub TR, Armstrong SA. Transformation from committed progenitor to 
leukaemia stem cell initiated by MLL-AF9. Nature 2006; 442:818-22.
 22. Ziemin-van der Poel S, McCabe NR, Gill HJ, Espinosa R, III, Patel Y, Harden A, Rubinelli P, 
Smith SD, LeBeau MM, Rowley JD, et al. Identification of a gene, MLL, that spans the 
breakpoint in 11q23 translocations associated with human leukemias. Proc Natl Acad Sci 
USA 1991; 88:10735-9.
 23. Gu Y, Nakamura T, Alder H, Prasad R, Canaani O, Cimino G, Croce CM, Canaani E. The 
t(4;11) chromosome translocation of human acute leukemias fuses the ALL-1 gene, related 
to Drosophila trithorax, to the AF-4 gene. Cell 1992; 71:701-8.
 24. Tkachuk DC, Kohler S, Cleary ML. Involvement of a homolog of Drosophila trithorax by 
11q23 chromosomal translocations in acute leukemias. Cell 1992; 71:691-700.
 25. Domer PH, Fakharzadeh SS, Chen CS, Jockel J, Johansen L, Silverman GA, Kersey JH, 
Korsmeyer SJ. Acute mixed-lineage leukemia t(4;11)(q21;q23) generates an MLL-AF4 
fusion product. Proc Natl Acad Sci USA 1993; 90:7884-8.
 26. Thirman MJ, Gill HJ, Burnett RC, Mbangkollo D, McCabe NR, Kobayashi H, Ziemin-
van der Poel S, Kaneko Y, Morgan R, Sandberg AA, et al. Rearrangement of the MLL gene 
in acute lymphoblastic and acute myeloid leukemias with 11q23 chromosomal transloca-
tions. N Engl J Med 1993; 329:909-14.
 27. Djabali M, Selleri L, Parry P, Bower M, Young B, Evans GA. A trithorax-like gene is inter-
rupted by chromosome 11q23 translocations in acute leukaemias. Nat Genet 1993; 4:431.
 28. Yu BD, Hanson RD, Hess JL, Horning SE, Korsmeyer SJ. MLL, a mammalian trithorax-
group gene, functions as a transcriptional maintenance factor in morphogenesis. Proc Natl 
Acad Sci USA 1998; 95:10632-6.
 29. Ringrose L, Paro R. Epigenetic regulation of cellular memory by the Polycomb and 
Trithorax group proteins. Annu Rev Genet 2004; 38:413-43.
 30. Schuettengruber B, Chourrout D, Vervoort M, Leblanc B, Cavalli G. Genome regulation 
by polycomb and trithorax proteins. Cell 2007; 128:735-45.
 31. Yu BD, Hess JL, Horning SE, Brown GA, Korsmeyer SJ. Altered Hox expression and seg-
mental identity in Mll-mutant mice. Nature 1995; 378:505-8.
 32. Yagi H, Deguchi K, Aono A, Tani Y, Kishimoto T, Komori T. Growth disturbance in fetal 
liver hematopoiesis of Mll-mutant mice. Blood 1998; 92:108-17.
 33. Ayton P, Sneddon SF, Palmer DB, Rosewell IR, Owen MJ, Young B, Presley R, Subramanian V. 
Truncation of the Mll gene in exon 5 by gene targeting leads to early preimplantation lethal-
ity of homozygous embryos. Genesis 2001; 30:201-12.
 34. Jude C, Climer L, Xu D, Artinger E, Fisher J, Ernst P. Unique and independent roles for 
MLL in adult hematopoietic stem cells and progenitors. Cell Stem Cell 2007; 1:324-37.
 35. McMahon KA, Samantha Y.-L. Hiew, Hadjur S, Veiga-Fernandes H, Menzel U, Price AJ, 
Kioussis D, Williams O, Brady HJM. MLL Has a Critical Role in Fetal and Adult 
Hematopoietic Stem Cell Self-Renewal Cell Stem. Cell 2007; 1:338-45.
 36. Zeleznik-Le NJ, Harden AM, Rowley JD. 11q23 translocations split the “AT-hook” 
cruciform DNA-binding region and the transcriptional repression domain from the activa-
tion domain of the mixed-lineage leukemia (MLL) gene. Proc Natl Acad Sci USA 1994; 
91:10610-4.
 37. Xia ZB, Anderson M, Diaz MO, Zeleznik-Le NJ. MLL repression domain interacts with 
histone deacetylases, the polycomb group proteins HPC2 and BMI-1, and the corepressor 
C-terminal-binding protein. Proc Natl Acad Sci USA 2003; 100:8342-7.
 38. Fair K, Anderson M, Bulanova E, Mi H, Tropschug M, Diaz MO. Protein interactions of 
the MLL PHD fingers modulate MLL target gene regulation in human cells. Mol Cell Biol 
2001; 21:3589-97.
 39. Ernst P, Wang J, Huang M, Goodman RH, Korsmeyer SJ. MLL and CREB bind coopera-
tively to the nuclear coactivator CREB-binding protein. Mol Cell Biol 2001; 21:2249-58.
 40. Milne TA, Briggs SD, Brock HW, Martin ME, Gibbs D, Allis CD, Hess JL. MLL 
targets SET domain methyltransferase activity to Hox gene promoters. Mol Cell 2002; 
10:1107-17.
 41. Nakamura T, Mori T, Tada S, Krajewski W, Rozovskaia T, Wassell R, Dubois G, Mazo A, 
Croce CM, Canaani E. ALL-1 is a histone methyltransferase that assembles a supercomplex 
of proteins involved in transcriptional regulation. Mol Cell 2002; 10:1119-28.
 42. Hughes CM, Rozenblatt-Rosen O, Milne TA, Copeland TD, Levine SS, Lee JC, Hayes DN, 
Shanmugam KS, Bhattacharjee A, Biondi CA, Kay GF, Hayward NK, Hess JL, Meyerson M. 
Menin associates with a trithorax family histone methyltransferase complex and with the 
hoxc8 locus. Mol Cell 2004; 13:587-97.
 43. Yokoyama A, Wang Z, Wysocka J, Sanyal M, Aufiero DJ, Kitabayashi I, Herr W, Cleary ML. 
Leukemia proto-oncoprotein MLL forms a SET1-like histone methyltransferase complex 
with menin to regulate Hox gene expression. Mol Cell Biol 2004; 24:5639-49.
 44. Takeda S, Chen DY, Westergard TD, Fisher JK, Rubens JA, Sasagawa S, Kan JT, Korsmeyer SJ, 
Cheng EH, Hsieh JJ. Proteolysis of MLL family proteins is essential for taspase1-orches-
trated cell cycle progression. Genes Dev 2006; 20:2397-409.
Figure 4. A diagram highlights the intricate relationship and draws the anal-
ogy between MLL, a Trx-G protein and Bmi-1, a Pc-G protein, in embryogen-
esis and oncogenesis.
Mll in the cell cycle driver’s seat
434 Cell Cycle 2008; Vol. 7 Issue 4
 45. Tyagi S, Chabes AL, Wysocka J, Herr W. E2F activation of S phase promoters via associa-
tion with HCF-1 and the MLL family of histone H3K4 methyltransferases. Mol Cell 2007; 
27:107-19.
 46. Rozenblatt-Rosen O, Rozovskaia T, Burakov D, Sedkov Y, Tillib S, Blechman J, Nakamura T, 
Croce CM, Mazo A, Canaani E. The C-terminal SET domains of ALL-1 and TRITHORAX 
interact with the INI1 and SNR1 proteins, components of the SWI/SNF complex. Proc 
Natl Acad Sci USA 1998; 95:4152-7.
 47. Dou Y, Milne TA, Tackett AJ, Smith ER, Fukuda A, Wysocka J, Allis CD, Chait BT, 
Hess JL, Roeder RG. Physical Association and Coordinate Function of the H3 K4 
Methyltransferase MLL1 and the H4 K16 Acetyltransferase MOF. Cell 2005; 121:873-85.
 48. Dou Y, Milne TA, Ruthenburg AJ, Lee S, Lee JW, Verdine GL, Allis CD, Roeder RG. 
Regulation of MLL1 H3K4 methyltransferase activity by its core components. Nat Struct 
Mol Biol 2006; 13:713-9.
 49. Yokoyama A, Kitabayashi I, Ayton PM, Cleary ML, Ohki M. Leukemia proto-oncoprotein 
MLL is proteolytically processed into 2 fragments with opposite transcriptional properties. 
Blood 2002; 100:3710-8.
 50. Hsieh JJ, Ernst P, Erdjument-Bromage H, Tempst P, Korsmeyer SJ. Proteolytic cleavage of 
MLL generates a complex of N- and C-terminal fragments that confers protein stability and 
subnuclear localization. Mol Cell Biol 2003; 23:186-94.
 51. Hsieh JJ, Cheng EH, Korsmeyer SJ. Taspase1: a threonine aspartase required for cleavage of 
MLL and proper HOX gene expression. Cell 2003; 115:293-303.
 52. Khan JA, Dunn BM, Tong L. Crystal structure of human Taspase1, a crucial protease regu-
lating the function of MLL. Structure 2005; 13:1443-52.
 53. Capotosti F, Hsieh JJ, Herr W. Species selectivity of mixed-lineage leukemia/trithorax and 
HCF proteolytic maturation pathways. Mol Cell Biol 2007; 27:7063-72.
 54. Zhou H, Spicuglia S, Hsieh JJ, Mitsiou DJ, Hoiby T, Veenstra GJ, Korsmeyer SJ, 
Stunnenberg HG. Uncleaved TFIIA is a substrate for taspase 1 and active in transcription. 
Mol Cell Biol 2006; 26:2728-35.
 55. Mazo AM, Huang DH, Mozer BA, Dawid IB. The trithorax gene, a trans-acting regulator 
of the bithorax complex in Drosophila, encodes a protein with zinc-binding domains. Proc 
Natl Acad Sci USA 1990; 87:2112-6.
 56. Hess JL, Yu BD, Li B, Hanson R, Korsmeyer SJ. Defects in yolk sac hematopoiesis in Mll-
null embryos. Blood 1997; 90:1799-806.
 57. Nurse P. A long twentieth century of the cell cycle and beyond. Cell 2000; 100:71-8.
 58. Murray AW. Recycling the cell cycle: cyclins revisited. Cell 2004; 116:221-34.
 59. Morgan DO. Cyclin-dependent kinases: engines, clocks, and microprocessors. Annu Rev 
Cell Dev Biol 1997; 13:261-91.
 60. Dyson N. The regulation of E2F by pRB-family proteins. Genes Dev 1998; 12:2245-62.
 61. Nevins JR. The Rb/E2F pathway and cancer. Hum Mol Genet 2001; 10:699-703.
 62. Trimarchi JM, Lees JA. Sibling rivalry in the E2F family. Nat Rev Mol Cell Biol 2002; 
3:11-20.
 63. Bracken AP, Ciro M, Cocito A, Helin K. E2F target genes: unraveling the biology. Trends 
Biochem Sci 2004; 29:409-17.
 64. Giacinti C, Giordano A. RB and cell cycle progression. Oncogene 2006; 25:5220-7.
 65. Sherr CJ, Roberts JM. CDK inhibitors: positive and negative regulators of G1 -phase pro-
gression. Genes Dev 1999; 13:1501-12.
 66. Reed SI. Ratchets and clocks: the cell cycle, ubiquitylation and protein turnover. Nat Rev 
Mol Cell Biol 2003; 4:855-64.
 67. Hershko A. The ubiquitin system for protein degradation and some of its roles in the con-
trol of the cell division cycle. Cell Death Differ 2005; 12:1191-7.
 68. Cardozo T, Pagano M. The SCF ubiquitin ligase: insights into a molecular machine. Nat 
Rev Mol Cell Biol 2004; 5:739-51.
 69. Nakayama KI, Nakayama K. Ubiquitin ligases: cell cycle control and cancer. Nat Rev 
Cancer 2006; 6:369-81.
 70. Peters JM. The anaphase promoting complex/cyclosome: a machine designed to destroy. 
Nat Rev Mol Cell Biol 2006; 7:644-56.
 71. Muyrers-Chen I, Rozovskaia T, Lee N, Kersey JH, Nakamura T, Canaani E, Paro R. 
Expression of leukemic MLL fusion proteins in Drosophila affects cell cycle control and 
chromosome morphology. Oncogene 2004; 23:8639-48.
 72. Xia ZB, Popovic R, Chen J, Theisler C, Stuart T, Santillan DA, Erfurth F, Diaz MO, 
Zeleznik-Le NJ. The MLL fusion gene, MLL-AF4, regulates cyclin-dependent kinase 
inhibitor CDKN1B (p27kip1) expression. Proc Natl Acad Sci USA 2005; 102:14028-33.
 73. Milne TA, Hughes CM, Lloyd R, Yang Z, Rozenblatt-Rosen O, Dou Y, Schnepp RW, 
Krankel C, Livolsi VA, Gibbs D, Hua X, Roeder RG, Meyerson M, Hess JL. Menin and 
MLL cooperatively regulate expression of cyclin-dependent kinase inhibitors. Proc Natl 
Acad Sci USA 2005; 102:749-54.
 74. Liu H, Cheng EH, Hsieh JJ. Bimodal degradation of MLL by SCFSkp2 and APCCdc20 
assures cell cycle execution: a critical regulatory circuit lost in leukemogenic MLL fusions. 
Genes Dev 2007; 21:2385-98.
 75. Caslini C, Shilatifard A, Yang L, Hess JL. The amino terminus of the mixed lineage leuke-
mia protein (MLL) promotes cell cycle arrest and monocytic differentiation. Proc Natl Acad 
Sci USA 2000; 97:2797-802.
 76. Nakayama KI, Hatakeyama S, Nakayama K. Regulation of the cell cycle at the G1-S 
transition by proteolysis of cyclin E and p27Kip1. Biochem Biophys Res Commun 2001; 
282:853-60.
 77. Corral J, Lavenir I, Impey H, Warren AJ, Forster A, Larson TA, Bell S, McKenzie AN, King G, 
Rabbitts TH. An Mll-AF9 fusion gene made by homologous recombination causes acute 
leukemia in chimeric mice: a method to create fusion oncogenes. Cell 1996; 85:853-61.
 78. Dobson CL, Warren AJ, Pannell R, Forster A, Lavenir I, Corral J, Smith AJ, Rabbitts TH. 
The mll-AF9 gene fusion in mice controls myeloproliferation and specifies acute myeloid 
leukaemogenesis. Embo J 1999; 18:3564-74.
 79. Forster A, Pannell R, Drynan L, Cano F, Chan N, Codrington R, Daser A, Lobato N, 
Metzler M, Nam CH, Rodriguez S, Tanaka T, Rabbitts T. Chromosomal translocation 
engineering to recapitulate primary events of human cancer. Cold Spring Harb Symp Quant 
Biol 2005; 70:275-82.
 80. Chen W, Li Q, Hudson WA, Kumar A, Kirchhof N, Kersey JH. A murine Mll-AF4 knock-
in model results in lymphoid and myeloid deregulation and hematologic malignancy. Blood 
2006; 108:669-77.
 81. Wang J, Iwasaki H, Krivtsov A, Febbo PG, Thorner AR, Ernst P, Anastasiadou E, Kutok JL, 
Kogan SC, Zinkel SS, Fisher JK, Hess JL, Golub TR, Armstrong SA, Akashi K, Korsmeyer SJ. 
Conditional MLL-CBP targets GMP and models therapy-related myeloproliferative disease. 
Embo J 2005; 24:368-81.
 82. Dobson CL, Warren AJ, Pannell R, Forster A, Rabbitts TH. Tumorigenesis in mice 
with a fusion of the leukaemia oncogene Mll and the bacterial lacZ gene. Embo J 2000; 
19:843-51.
 83. Metzler M, Forster A, Pannell R, Arends MJ, Daser A, Lobato MN, Rabbitts TH. A con-
ditional model of MLL-AF4 B-cell tumourigenesis using invertor technology. Oncogene 
2006; 25:3093-103.
 84. Lavau C, Szilvassy SJ, Slany R, Cleary ML. Immortalization and leukemic transforma-
tion of a myelomonocytic precursor by retrovirally transduced HRX-ENL. Embo J 1997; 
16:4226-37.
 85. Slany RK, Lavau C, Cleary ML. The oncogenic capacity of HRX-ENL requires the tran-
scriptional transactivation activity of ENL and the DNA binding motifs of HRX. Mol Cell 
Biol 1998; 18:122-9.
 86. DiMartino JF, Miller T, Ayton PM, Landewe T, Hess JL, Cleary ML, Shilatifard A. A 
carboxy-terminal domain of ELL is required and sufficient for immortalization of myeloid 
progenitors by MLL-ELL. Blood 2000; 96:3887-93.
 87. Lavau C, Du C, Thirman M, Zeleznik-Le N. Chromatin-related properties of CBP fused to 
MLL generate a myelodysplastic-like syndrome that evolves into myeloid leukemia. Embo 
J 2000; 19:4655-64.
 88. Lavau C, Luo RT, Du C, Thirman MJ. Retrovirus-mediated gene transfer of MLL-ELL 
transforms primary myeloid progenitors and causes acute myeloid leukemias in mice. Proc 
Natl Acad Sci USA 2000; 97:10984-9.
 89. DiMartino JF, Ayton PM, Chen EH, Naftzger CC, Young BD, Cleary ML. The AF10 leu-
cine zipper is required for leukemic transformation of myeloid progenitors by MLL-AF10. 
Blood 2002; 99:3780-5.
 90. So CW, Cleary ML. MLL-AFX requires the transcriptional effector domains of AFX to 
transform myeloid progenitors and transdominantly interfere with forkhead protein func-
tion. Mol Cell Biol 2002; 22:6542-52.
 91. So CW, Lin M, Ayton PM, Chen EH, Cleary ML. Dimerization contributes to oncogenic 
activation of MLL chimeras in acute leukemias. Cancer Cell 2003; 4:99-110.
 92. Martin ME, Milne TA, Bloyer S, Galoian K, Shen W, Gibbs D, Brock HW, Slany R, Hess JL. 
Dimerization of MLL fusion proteins immortalizes hematopoietic cells. Cancer Cell 2003; 
4:197-207.
 93. Krumlauf R. Hox genes in vertebrate development. Cell 1994; 78:191-201.
 94. Lawrence HJ, Sauvageau G, Humphries RK, Largman C. The role of HOX homeobox 
genes in normal and leukemic hematopoiesis. Stem Cells 1996; 14:281-91.
 95. Ayton PM, Cleary ML. Transformation of myeloid progenitors by MLL oncoproteins is 
dependent on Hoxa7 and Hoxa9. Genes Dev 2003; 17:2298-307.
 96. So CW, Karsunky H, Wong P, Weissman IL, Cleary ML. Leukemic transformation of 
hematopoietic progenitors by MLL-GAS7 in the absence of Hoxa7 or Hoxa9. Blood 2004; 
103:3192-9.
 97. Kumar AR, Hudson WA, Chen W, Nishiuchi R, Yao Q, Kersey JH. Hoxa9 influences 
the phenotype but not the incidence of Mll-AF9 fusion gene leukemia. Blood 2004; 
103:1823-8.
 98. Caslini C, Yang Z, El-Osta M, Milne TA, Slany RK, Hess JL. Interaction of MLL 
amino terminal sequences with menin is required for transformation. Cancer Res 2007; 
67:7275-83.
 99. Caslini C, Serna A, Rossi V, Introna M, Biondi A. Modulation of cell cycle by graded 
expression of MLL-AF4 fusion oncoprotein. Leukemia 2004; 18:1064-71.
 100. Eguchi M, Eguchi-Ishimae M, Knight D, Kearney L, Slany R, Greaves M. MLL chimeric 
protein activation renders cells vulnerable to chromosomal damage: an explanation for the 
very short latency of infant leukemia. Genes Chromosomes Cancer 2006; 45:754-60.
 101. Pession A, Martino V, Tonelli R, Beltramini C, Locatelli F, Biserni G, Franzoni M, Freccero F, 
Montemurro L, Pattacini L, Paolucci G. MLL-AF9 oncogene expression affects cell growth 
but not terminal differentiation and is downregulated during monocyte-macrophage matu-
ration in AML-M5 THP-1 cells. Oncogene 2003; 22:8671-6.
 102. Martinez AM, Colomb S, Dejardin J, Bantignies F, Cavalli G. Polycomb group-dependent 
Cyclin A repression in Drosophila. Genes Dev 2006; 20:501-13.
 103. van Lohuizen M, Verbeek S, Scheijen B, Wientjens E, van der Gulden H, Berns A. 
Identification of cooperating oncogenes in E mu-myc transgenic mice by provirus tagging. 
Cell 1991; 65:737-52.
Mll in the cell cycle driver’s seat
www.landesbioscience.com Cell Cycle 435
 104. Park IK, Qian D, Kiel M, Becker MW, Pihalja M, Weissman IL, Morrison SJ, Clarke MF. 
Bmi-1 is required for maintenance of adult self-renewing haematopoietic stem cells. Nature 
2003; 423:302-5.
 105. Pardal R, Molofsky AV, He S, Morrison SJ. Stem cell self-renewal and cancer cell prolifera-
tion are regulated by common networks that balance the activation of proto-oncogenes and 
tumor suppressors. Cold Spring Harb Symp Quant Biol 2005; 70:177-85.
 106. Jacobs JJ, Kieboom K, Marino S, DePinho RA, van Lohuizen M. The oncogene and 
Polycomb-group gene bmi-1 regulates cell proliferation and senescence through the ink4a 
locus. Nature 1999; 397:164-8.
